Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer

被引:93
作者
Jeon, Yoon Kyung
Sung, Sook-Whan
Chung, Jin-Haeng
Park, Weon-Seo
Seo, Jeong-Wook
Kim, Chul Woo
Chung, Doo Hyun
机构
[1] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Thorac Surg, Sungham, Gyeonggi Do, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Sungham, Gyeonggi Do, South Korea
[4] Seoul Natl Univ, Coll Med, Canc Res Inst, Tumor Immun Med Res Ctr, Seoul, South Korea
[5] Natl Canc Ctr, Dept Pathol, Seoul, South Korea
关键词
epidermal growth; factor receptor; FISH; gene copy number; gene amplification; non-small cell lung cancer;
D O I
10.1016/j.lungcan.2006.08.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased epidermal growth factor receptor (EGFR) gene copy numbers and mutations predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell tung cancer (NSCLC). However, the clinicopathologic features of EGFR gene copy status in NSCLC remain unclear. We retrospectively analyzed 262 cases of NSCLC, including 135 squamous cell carcinomas (SCC) and 112 adenocarcinomas (ADC), for which paraffin blocks of the resected primary lung mass were available. None had received EGFR-targeted therapy. EGFR gene copy number was evaluated using fluorescence in situ hybridization (FISH), and EGFR expression was determined immunohistochemically using a tissue microarray. A high EGFR gene copy (EGFR FISH-positive) was found in 30.2% of the cases (amplification in 11.1% and high polysomy in 19.1%). There was no significant difference in EGFR FISH status with respect to SCC and ADC histology. The EGFR FISH-positive rate was higher in non-smokers than in smokers in the multivariate analysis (p=0.012). EGFR expression was significantly associated with a high EGFR gene copy and SCC histology (p=0.000). In the univariate survival analysis, EGFR FISH-positivity predicted worse survival in SCC (p=0.059), especially stage I SCC (p=0.04). EGFR amplification was associated with a shorter survival in node-positive SCC (p = 0.015). However, the EGFR gene copy number or protein expression had no influence on the prognosis of ADC. In conclusion, the EGFR FISH-positive rate in Korean patients with NSCLC was similar to rates in Western populations, unlike the higher frequencies of EGFR mutation in East Asians. A high EGFR gene copy number was significantly more common in non-smokers, as were EGFR mutations. A high EGFR gene copy number predicted worse survival in SCC; therefore, the prognostic implications of the EGFR gene and protein should be analyzed in the context of histology and staging in NSCLC. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:387 / 398
页数:12
相关论文
共 37 条
  • [1] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [2] Amann J, 2005, CANCER RES, V65, P226
  • [3] Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
    Cappuzzo, F
    Gregorc, V
    Rossi, E
    Cancellieri, A
    Magrini, E
    Paties, CT
    Ceresoli, G
    Lombardo, L
    Bartolini, S
    Calandri, C
    De Rosa, M
    Villa, E
    Crinò, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2658 - 2663
  • [4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [5] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Cappuzzo, F
    Magrini, E
    Ceresoli, GL
    Bartolini, S
    Rossi, E
    Ludovini, V
    Gregorc, V
    Ligorio, C
    Cancellieri, A
    Damiani, S
    Spreafico, A
    Paties, CT
    Lombardo, L
    Calandri, C
    Bellezza, G
    Tonato, M
    Crinò, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141
  • [6] COHEN S, 1982, J BIOL CHEM, V257, P1523
  • [7] Molecular pathogenesis of lung cancer
    Fong, KM
    Sekido, Y
    Minna, JD
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (06) : 1136 - 1152
  • [8] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
  • [9] Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Han, SW
    Kim, TY
    Jeon, YK
    Hwang, PG
    Im, SA
    Lee, KH
    Kim, JH
    Kim, DW
    Heo, DS
    Kim, NK
    Chung, DH
    Bang, YJ
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2538 - 2544
  • [10] Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Han, SW
    Kim, TY
    Hwang, PG
    Jeong, S
    Kim, J
    Choi, IS
    Oh, DY
    Kim, LH
    Kim, DW
    Chung, DH
    Im, SA
    Kim, YT
    Lee, JS
    Heo, DS
    Bang, YJ
    Kim, NK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2493 - 2501